Latest Insider Transactions at Alnylam Pharmaceuticals, Inc. (ALNY)
This section provides a real-time view of insider transactions for Alnylam Pharmaceuticals, Inc. (ALNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALNYLAM PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALNYLAM PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 20
2021
|
Akshay Vaishnaw President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,351
-6.15%
|
$312,683
$133.15 P/Share
|
|
Apr 20
2021
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,383
-15.54%
|
$183,939
$133.12 P/Share
|
|
Apr 19
2021
|
John Maraganore Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,236
+6.81%
|
-
|
|
Apr 19
2021
|
Laurie Keating EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,518
+33.53%
|
-
|
|
Apr 19
2021
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,083
+27.54%
|
-
|
|
Apr 19
2021
|
Akshay Vaishnaw President |
SELL
Open market or private sale
|
Direct |
3,706
-4.3%
|
$511,428
$138.26 P/Share
|
|
Apr 19
2021
|
Akshay Vaishnaw President |
BUY
Grant, award, or other acquisition
|
Direct |
5,083
+18.16%
|
-
|
|
Apr 19
2021
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,518
+50.0%
|
-
|
|
Feb 25
2021
|
John Maraganore Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,979
-1.37%
|
$5,062,871
$149.18 P/Share
|
|
Feb 25
2021
|
John Maraganore Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,979
+12.4%
|
$237,853
$7.1 P/Share
|
|
Feb 12
2021
|
Laurie Keating EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,963
-15.67%
|
$302,302
$154.77 P/Share
|
|
Feb 12
2021
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-9.61%
|
$301,475
$155.92 P/Share
|
|
Feb 12
2021
|
John Maraganore Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,719
-1.35%
|
$875,007
$153.97 P/Share
|
|
Feb 12
2021
|
Akshay Vaishnaw President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,710
-4.4%
|
$263,340
$154.26 P/Share
|
|
Feb 11
2021
|
Laurie Keating EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,166
+39.43%
|
-
|
|
Feb 11
2021
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,416
+34.6%
|
-
|
|
Feb 11
2021
|
John Maraganore Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,166
+6.27%
|
-
|
|
Feb 11
2021
|
Akshay Vaishnaw President |
BUY
Grant, award, or other acquisition
|
Direct |
5,416
+21.71%
|
-
|
|
Jan 13
2021
|
Laurie Keating EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,027
-41.27%
|
$1,543,617
$171.0 P/Share
|
|
Jan 13
2021
|
Laurie Keating EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,027
+35.64%
|
$731,187
$81.2 P/Share
|
|
Jan 12
2021
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,125
-39.33%
|
$503,125
$161.0 P/Share
|
|
Jan 12
2021
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+28.23%
|
$131,250
$42.22 P/Share
|
|
Jan 12
2021
|
Laurie Keating EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
14,941
-63.42%
|
$2,420,442
$162.0 P/Share
|
|
Jan 12
2021
|
Laurie Keating EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,941
+37.41%
|
$881,519
$59.81 P/Share
|
|
Jan 11
2021
|
Laurie Keating EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
758
-25.33%
|
$116,732
$154.0 P/Share
|
|
Dec 18
2020
|
Steven M Paul Director |
SELL
Open market or private sale
|
Direct |
15,000
-93.75%
|
$2,100,000
$140.0 P/Share
|
|
Dec 18
2020
|
Steven M Paul Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+48.39%
|
$135,000
$9.3 P/Share
|
|
Dec 07
2020
|
Phillip A Sharp Director |
BUY
Bona fide gift
|
Indirect |
235,633
+46.89%
|
-
|
|
Dec 07
2020
|
Phillip A Sharp Director |
SELL
Bona fide gift
|
Direct |
235,633
-100.0%
|
-
|
|
Nov 25
2020
|
Phillip A Sharp Director |
SELL
Open market or private sale
|
Direct |
30,000
-2.92%
|
$3,750,000
$125.74 P/Share
|
|
Nov 25
2020
|
Phillip A Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.15%
|
$270,000
$9.3 P/Share
|
|
Nov 19
2020
|
John Maraganore Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,765
-3.92%
|
$4,345,625
$125.0 P/Share
|
|
Nov 19
2020
|
John Maraganore Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,765
+13.01%
|
$312,885
$9.14 P/Share
|
|
Sep 29
2020
|
Akshay Vaishnaw President |
SELL
Open market or private sale
|
Direct |
971
-6.43%
|
$135,940
$140.0 P/Share
|
|
Sep 29
2020
|
Akshay Vaishnaw President |
BUY
Exercise of conversion of derivative security
|
Direct |
971
+6.05%
|
$40,782
$42.22 P/Share
|
|
Oct 10
2019
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Other acquisition or disposition
|
Indirect |
38
+50.0%
|
-
|
|
May 31
2017
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
297,501
+2.74%
|
$21,122,571
$71.87 P/Share
|
|
Feb 01
2016
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
205,030
+1.96%
|
$14,147,070
$69.75 P/Share
|
|
Jan 29
2015
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
97,118
+0.96%
|
$9,226,210
$95.0 P/Share
|
|
Jan 26
2015
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
647,448
+6.11%
|
$61,507,560
$95.0 P/Share
|
|
Jan 22
2015
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
196,251
+2.07%
|
$1,828,470,567
$9317.0 P/Share
|
|
Mar 25
2014
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
344,448
+3.64%
|
$22,733,568
$66.88 P/Share
|
|
Sep 20
2012
|
Ag Novartis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,551,896
-27.7%
|
$29,486,024
$19.42 P/Share
|
|
Apr 23
2010
|
Ag Novartis > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
55,223
+0.98%
|
$938,791
$17.99 P/Share
|
|
May 06
2009
|
Ag Novartis > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
65,922
+1.17%
|
$1,120,674
$17.5 P/Share
|
|
May 08
2008
|
Ag Novartis > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
213,888
+3.76%
|
$5,347,200
$25.29 P/Share
|